BRCA1 and neoplasm: Further strengthening the anti‐tumour activity of pyridostatin against PARPi‐resistant tumours is its inhibitory effect against BRCA1‐deleted PDTXs, which carry inactivating mutations in the REV7 (MAD2L2) gene (Bruna et al, 2016).